371 related articles for article (PubMed ID: 36671569)
1. Single-Cell Profiling Comparisons of Tumor Microenvironment between Primary Advanced Lung Adenocarcinomas and Brain Metastases and Machine Learning Algorithms in Predicting Immunotherapeutic Responses.
Wu Y; Kang K; Han C; Wang L; Wang Z; Zhao A
Biomolecules; 2023 Jan; 13(1):. PubMed ID: 36671569
[TBL] [Abstract][Full Text] [Related]
2. Integrating bulk-RNA sequencing and single-cell sequencing analyses to characterize adenosine-enriched tumor microenvironment landscape and develop an adenosine-related prognostic signature predicting immunotherapy in lung adenocarcinoma.
Han T; Wu J; Liu Y; Zhou J; Miao R; Guo J; Xu Z; Xing Y; Bai Y; Hu D
Funct Integr Genomics; 2024 Jan; 24(1):19. PubMed ID: 38265702
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Analysis of Lung Adenocarcinoma and Brain Metastasis through Integrated Single-Cell Transcriptomics.
Souza VGP; Telkar N; Lam WL; Reis PP
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612588
[TBL] [Abstract][Full Text] [Related]
4. Single-cell RNA sequencing reveals the effects of anti-PD-L1 therapy on 3LL lung cancer model and its tumor microenvironment.
Zhang H; Huang H; Wu S; He X; Chen J; Zheng X; Chen L; Wang Z
Med Oncol; 2023 Aug; 40(10):285. PubMed ID: 37653265
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
6. Single-cell dissection reveals the role of aggrephagy patterns in tumor microenvironment components aiding predicting prognosis and immunotherapy on lung adenocarcinoma.
Sun X; Meng F; Nong M; Fang H; Lu C; Wang Y; Zhang P
Aging (Albany NY); 2023 Dec; 15(23):14333-14371. PubMed ID: 38095634
[TBL] [Abstract][Full Text] [Related]
7. Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues.
Fan TW; Higashi RM; Song H; Daneshmandi S; Mahan AL; Purdom MS; Bocklage TJ; Pittman TA; He D; Wang C; Lane AN
Elife; 2021 Aug; 10():. PubMed ID: 34406120
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma.
Xiao G; Li L; Tanzhu G; Liu Z; Gao X; Wan X; Xiao D; Chen L; Xia X; Zhou R
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36868569
[TBL] [Abstract][Full Text] [Related]
9. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
10. Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures.
Wu Q; Wang L; Wei H; Li B; Yang J; Wang Z; Xu J; Zhou YL; Zhang B
Int Immunopharmacol; 2020 Jun; 83():106477. PubMed ID: 32278127
[TBL] [Abstract][Full Text] [Related]
11. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
12. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
[TBL] [Abstract][Full Text] [Related]
13. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
Kim R; Keam B; Kim S; Kim M; Kim SH; Kim JW; Kim YJ; Kim TM; Jeon YK; Kim DW; Chung DH; Lee JS; Heo DS
BMC Cancer; 2019 Jan; 19(1):19. PubMed ID: 30616523
[TBL] [Abstract][Full Text] [Related]
14. Tumor Immune Microenvironment and Immunotherapy in Brain Metastasis From Non-Small Cell Lung Cancer.
Wang Y; Chen R; Wa Y; Ding S; Yang Y; Liao J; Tong L; Xiao G
Front Immunol; 2022; 13():829451. PubMed ID: 35251014
[TBL] [Abstract][Full Text] [Related]
15. [
Zhang Z; Tan J; Yu Z; Liu C; Wang J; Wu D; Bai X
Nan Fang Yi Ke Da Xue Xue Bao; 2023 May; 43(5):667-679. PubMed ID: 37313807
[TBL] [Abstract][Full Text] [Related]
16. Homologous recombination deficiency in triple-negative breast cancer: Multi-scale transcriptomics reveals distinct tumor microenvironments and limitations in predicting immunotherapy response.
Kang K; Wu Y; Han C; Wang L; Wang Z; Zhao A
Comput Biol Med; 2023 May; 158():106836. PubMed ID: 37031511
[TBL] [Abstract][Full Text] [Related]
17. Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060).
Li M; Hou X; Sai K; Wu L; Chen J; Zhang B; Wang N; Wu L; Zheng H; Zhang J; Mou Y; Chen L
Oncoimmunology; 2022; 11(1):2059874. PubMed ID: 35402080
[TBL] [Abstract][Full Text] [Related]
18. Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival.
Pocha K; Mock A; Rapp C; Dettling S; Warta R; Geisenberger C; Jungk C; Martins LR; Grabe N; Reuss D; Debus J; von Deimling A; Abdollahi A; Unterberg A; Herold-Mende CC
Clin Cancer Res; 2020 May; 26(9):2231-2243. PubMed ID: 31953311
[TBL] [Abstract][Full Text] [Related]
19. Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma.
Liu J; Shen H; Gu W; Zheng H; Wang Y; Ma G; Du J
Front Immunol; 2022; 13():960738. PubMed ID: 36032135
[TBL] [Abstract][Full Text] [Related]
20. Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
Larroquette M; Guegan JP; Besse B; Cousin S; Brunet M; Le Moulec S; Le Loarer F; Rey C; Soria JC; Barlesi F; Bessede A; Scoazec JY; Soubeyran I; Italiano A
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
